DE KOCK, HERMAN AUGUSTINUS,SIMMEN, KENNETH ALAN,JOENSSON, CARL ERIK DANIEL,AYESA ALVAREZ, SUSANA,CLASSON, BJOERN OLOF,NILSSON, KARL MAGNUS,ROSENQUIST, ASA ANNICA KRISTINA,SAMUELSSON, BENGT BERTIL,WALL
申请号：
CA2617099
公开号：
CA2617099C
申请日:
2006.07.28
申请国别(地区):
CA
年份:
2014
代理人:
摘要：
Inhibitors of HCV replication of formula (I) and the N-oxides, salts, orstereoisomers thereof, wherein each dashed line represents an optional doublebond X is N, CH and where X bears a double bond it is C R1 is -OR6, -NH-SO2R7 R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl R3 ishydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl n is 3, 4, 5, or6 R4 and R5 taken together with the nitrogen atom to which they are attachedform a bicyclic ring system selected from formula (II) wherein said ringsystem may optionally be substituted with 1-3 substituents R6 is hydrogenaryl Het C3-7cycloalkyl optionally substituted with C1-6alkyl or C1-6alkyloptionally substituted with C3-7cycloalkyl, aryl or with Het R7 is aryl HetC3-7cycloalkyl optionally substituted with C1-6alkyl or C1-6alkyl optionallysubstituted with C3-7cycloalkyl, aryl or with Het aryl is phenyl or naphthyl,each of which may be optionally substituted with 1-3 substituents Het is a 5or 6 membered saturated, partially unsaturated or completely unsaturatedheterocyclic ring containing 1 to 4 heteroatoms each independently selectedfrom N, O or S, and being optionally substituted with 1-3 substituentspharmaceutical compositions containing compounds (I) and processes forpreparing compounds (I). Bioavailable combinations of the inhibitors of HCV offormula (I) with ritonavir are also provided.
